Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen

AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.

While Boehringer Ingelheim Pharmaceuticals Inc. is the second company to win US approval of a biosimilar to AbbVie Inc.'s Humira (adalimumab), its launch date is uncertain given ongoing patent infringement litigation.

As a sign of the marketing delay, as of Aug. 2, the date AbbVie filed an infringement suit, BI had...